Articles published by Vistagen Therapeutics, Inc.
![](https://mms.businesswire.com/media/20231002934206/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
Vistagen Announces Pricing of $100 Million Underwritten Offering
October 02, 2023
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20221019005973/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
![](https://mms.businesswire.com/media/20221006005405/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20220909005140/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
Vistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences
September 09, 2022
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg)
![](https://mms.businesswire.com/media/20220811005677/en/1542358/4/VistaGen_logo_FINAL.jpg)
VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
August 11, 2022
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20220722005107/en/1521522/4/VistaGen_logo_FINAL.jpg)
![](https://mms.businesswire.com/media/20220712005491/en/1510666/4/VistaGen_logo_FINAL.jpg)
![](https://mms.businesswire.com/media/20220707005257/en/1506819/4/VistaGen_logo_FINAL.jpg)
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20220623005927/en/1495889/4/VistaGen_logo_FINAL.jpg)
![](https://mms.businesswire.com/media/20220622005431/en/1493682/4/VistaGen_logo_FINAL.jpg)
![](https://mms.businesswire.com/media/20220617005073/en/1489801/5/logo.jpg)
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20220602005364/en/1474306/4/VistaGen_logo_FINAL.jpg)
![](https://mms.businesswire.com/media/20220527005062/en/1469055/4/VistaGen_logo_FINAL.jpg)
Via Business Wire
Tickers
VTGN
![](https://mms.businesswire.com/media/20220505005461/en/1444776/4/VistaGen_logo_FINAL.jpg)
![](https://mms.businesswire.com/media/20220502005325/en/1439296/4/VistaGen_logo_FINAL.jpg)
![](https://mms.businesswire.com/media/20220421005424/en/1427903/4/VistaGen_logo_FINAL%5B1%5D.jpg)
VistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses
April 21, 2022
Via Business Wire
Tickers
VTGN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.